Annexon Biosciences announced the appointment of current board member William (Bill) Young, long-time biotech executive, as Chairman of the Board. In addition, Annexon has appointed Thomas (Tom) Wiggans, Chief Executive Officer of Dermira, Inc., as a new independent director on its Board of Directors. Mr. Young joined Annexon’s Board as an independent director in 2014. He currently serves as a Venture Partner at Clarus, after serving as Chief Executive Officer and Chairman of Monogram Biosciences from 1999 through to the sale of the company to LabCorp in 2009. Mr. Young also serves on the Board of Directors of Theravance Biopharma where he is Lead Director, Chairman of Nanostring Technologies and a director of Vertex Pharmaceuticals. Mr. Young previously served as Chairman of the Board of Biogen. Mr. Wiggans, a co-founder and current CEO of Dermira, Inc., brings over 30 years of experience in the pharmaceutical industry. Prior to founding Dermira, Mr. Wiggans served as Chairman of the Board of Directors and Chief Executive Officer of Peplin, Inc., which was acquired by LEO Pharma A/S in 2009. Mr. Wiggans previously served as Chairman of the Board of Directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc. in 2006. Prior to Connetics, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics Inc., and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans is a member of the Board of Directors of the Biotechnology Innovation Organization and has served on the boards of various industry organizations, educational institutions and private and public companies, including service on the Boards of Directors of Onyx Pharmaceuticals, Inc., until its acquisition by Amgen in 2013, Sangamo Biosciences, Inc. and Somaxon Pharmaceuticals, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.
ANNEXON, INC. 
